Non-Small Cell Lung Cancer (NSCLC) accounts for over 85% of lung cancer cases globally and remains one of the leading causes of cancer-related deaths. Early detection and longitudinal monitoring are critical, yet traditional tissue biopsies are invasive, costly, and limited in representing tumor heterogeneity.
Circulating tumor cells (CTCs) and circulating tumor microemboli (CTMs) have emerged as powerful biomarkers for real-time tumor profiling, treatment monitoring, and predicting metastasis risk. GBC’s CellBio™ a2000 platform addresses these needs by providing automated, size-based, label-free isolation of CTCs and CTMs — unlocking a new paradigm for precision oncology.
Study Overview: NSCLC Clinical Validation
In a prospective study involving 35 NSCLC patients, the CellBio™ a2000 system demonstrated its ability to reliably capture intact CTCs and CTMs from 7.5 ml of blood using patented iFiltration™ technology.
CellBio™ a2000 offers a robust, validated platform to facilitate clinical trials and companion diagnostics.
Future Directions
By integrating AI-assisted image analysis and multi-omic profiling pipelines, GBC is paving the way for next-generation personalized oncology solutions. Our collaborations with leading academic centers and biotech innovators further strengthen our ability to deliver clinically actionable insights.
Call-to-Action
Partner with GBC to harness the power of CellBio™ a2000 and drive breakthroughs in precision oncology.
GBC has been honored with the 2025 Taiwan Excellence Award for its CellBio™ FX10 system, a milestone in circulating tumor cell (CTC) detection. This prestigious award celebrates products that exemplify “innovation, design, quality, and marketability,” and underscores that CellBio™ FX10 sets the bar in diagnostic instrumentation.
Technical Innovation with Patented iFiltration™
Powered by GBC’s proprietary iFiltration™ technology, CellBio™ FX10 efficiently captures circulating tumor cells directly from minimal blood samples, achieving over 90% capture rate. This non-invasive, high-precision method supports early cancer detection and dynamic disease monitoring.
Impacting Cancer Research and Clinical Practice
With its automation and sensitivity, CellBio™ FX10 enables timely detection of tumor cells, aiding clinicians in treatment planning, patient monitoring, and early intervention—critical in precision oncology.
Comprehensive Recognition of GBC’s R&D Strength
Winning the Taiwan Excellence Award affirms GBC’s leadership in in vitro diagnostics, precision instrumentation, and oncology monitoring, reflecting our ongoing dedication to healthcare innovation.
Artificial intelligence is driving rapid advances in precision diagnostics, offering new tools to detect diseases faster, more accurately, and less invasively. One emerging application is AI-powered kidney stone screening, which uses routine health check data combined with machine learning algorithms to predict individual risk levels.
How the Technology Works
Unlike traditional methods such as X-rays or CT scans, which are costly, time-consuming, and involve radiation exposure, this AI-based system leverages non-invasive health data like:
Machine learning models then analyze these data points to predict kidney stone risk with impressive performance metrics. Recent studies have reported:
• Accuracy: 91.7%
• AUC: 96.7%
• Sensitivity: 87.3%
• Specificity: 94.5%
Clinical Implications
By offering fast and non-invasive risk assessment, AI-powered screening could:
• Identify high-risk patients earlier
• Reduce unnecessary imaging tests
• Optimize resource allocation in clinical workflows
• Improve patient outcomes through preventive intervention
Why This Matters for the Future
While GBC is not the developer of this technology, we closely track emerging innovations like AI-assisted diagnostics to understand their impact on healthcare ecosystems.
Advances in machine learning, digital health integration, and predictive analytics are shaping the next wave of personalized medicine, an area GBC actively explores through its own IVD, molecular diagnostics, and digital healthcare solutions.
Sarcomas are a group of rare malignant tumors arising from soft tissues such as fibrous tissue, fat, muscle, synovium, and connective tissues. They account for ~1% of all malignant tumors and mainly affect adults aged 20 to 60.
Epidemiology:
• U.S.: ~12,000 new cases annually
• Taiwan: ~500 new cases per year
• Common sites:
• Upper & lower limbs (~50%)
• Retroperitoneum & trunk (~40%)
• Head & neck (~10%)
• Special subtype: Gastrointestinal stromal tumors (GIST) originate from interstitial cells of Cajal, affecting the stomach, small intestine, colon, and rectum.
Causes and Risk Factors
• Unknown etiology in most cases
• Certain cases linked to trauma or prior radiation exposure
• Some linked to familial genetic syndromes and hereditary mutations
Clinical Presentation
• Extremity sarcomas: often present as painless subcutaneous masses
• Intra-abdominal sarcomas: frequently asymptomatic until tumors grow large enough to compress surrounding organs, nerves, or vessels
• Thoracic sarcomas: may cause respiratory discomfort
Patterns of Spread
• Direct invasion into surrounding tissues
• Hematogenous metastasis — most commonly to lungs and liver
• Lymphatic spread — extremely rare
CTC Analysis: A New Frontier in Sarcoma Diagnosis
Sarcoma’s heterogeneity and deep-seated tumor sites make early detection and treatment monitoring challenging. Traditional imaging may fail to identify micrometastases or detect early tumor spread.
Circulating Tumor Cells (CTCs) — cancer cells shed into the bloodstream — provide a real-time, minimally invasive diagnostic alternative.
Applications in Sarcoma Care:
• Early detection & staging → Detect potential metastasis before imaging
• Personalized medicine → Enable genomic profiling of CTCs to guide therapy
• Research insights → Study tumor heterogeneity, resistance, and progression patterns
Future Integration with Digital Health and AI
Combining CTC detection with AI-driven image analysis and multi-omic profiling enhances sensitivity and accuracy, particularly in rare cancers like sarcoma. This approach offers clinicians better tools for staging, monitoring, and optimizing personalized therapies.
GBC’s Commitment to Innovation
At GBC, we recognize the transformative potential of CTC analysis in sarcoma research and precision oncology. Our R&D ecosystem — spanning liquid biopsy, molecular diagnostics, and AI integration — is aligned with advancing non-invasive, real-time insights to support earlier detection and improved patient care.
GBC’s CellBio™ liquid biopsy platform has earned a Bronze Award in the Medical Device category at the National Pharmaceutical Technology & R&D Awards, a prestigious national program co-hosted by the Taiwan Food and Drug Administration (TFDA) and the Industrial Development Administration, MOEA. The award recognizes outstanding innovation, clinical potential, and industry impact.
CellBio™ uses patented iFiltration™ technology to automatically capture and preserve intact circulating tumor cells (CTCs) and other rare cells directly from blood samples.
This preserves cell morphology and protein expression, enabling downstream cytology, immunostaining, FISH, qPCR, NGS, and other multi-omic analyses, supporting precision oncology workflows.
Driving the Future of Precision Medicine
CellBio™ bridges research and clinical practice, empowering physicians with actionable insights for early detection, disease monitoring, and treatment evaluation.
This recognition reflects GBC’s leadership in automated intact-cell analysis and reinforces our commitment to innovation in translational medicine.
Looking Ahead
With an integrated ecosystem spanning R&D, manufacturing, clinical applications, and laboratory services, GBC is advancing CellBio™ solutions worldwide to make precision diagnostics more accessible and impactful.
The Genetic Nutrition & Functional Medicine Association, in collaboration with GBC and Leopard Gene, recently hosted a high-profile seminar titled “Precision Medicine in Comprehensive Health.” This well-attended event brought together experts across clinical and biotech fields to explore innovations propelling the future of healthcare.
Key themes discussed included:
1. Next-Generation CTC Detection: Exploring clinical use cases and emerging trends in capturing circulating tumor cells.
2. Advancements in Next-Generation Sequencing (NGS): Future applications and technology evolution.
3. Integrated Healthcare Models: Innovative approaches emerging in precision and preventive medicine.
Canada is increasingly embracing precision medicine alongside preventive approaches. GBC showcased its CellBio™ platform, drawing particular praise for its powerful clinical potential. Leveraging patented membrane filtration, the platform delivers over 90% tumor cell recovery, preserving complete cell morphology and enabling downstream applications like NGS, WGS, RT-PCR, cell culture, and anticancer drug sensitivity testing. Fully automated with no need for sample preprocessing, the system enhances downstream accuracy while reducing manual error—and it’s offered in both high-throughput (FX10) and compact (a2000) formats.
Looking ahead, GBC remains committed to advancing medical technology and driving precision medicine globally. We appreciate the enthusiasm and support of all participants in making this event a success.
The oral care industry has long lacked disruptive innovation. Leveraging decades of research, GBC introduces the P113 antimicrobial peptide, a breakthrough derived from the naturally occurring histatin-5 protein in human saliva.
With broad-spectrum antibacterial and antifungal properties, P113 selectively inhibits Streptococcus mutans and other oral pathogens, maintaining a healthy oral microbiome from the source.
Clinically Proven, Scientifically Validated
P113 is backed by clinical studies involving over 1,000 participants, demonstrating:
• Powerful antimicrobial efficacy — inhibits up to 90% of harmful oral bacteria
• Low allergenicity — safe for sensitive oral mucosa and skin
• Non-cytotoxicity — suitable for infants, pregnant women, and sensitive groups
• Globally recognized safety — data cited by international research institutions, aligning with global oral care standards
These findings make P113 a new-generation antimicrobial solution combining safety and efficacy.
Introducing the oh care® Oral Care Series
Through its subsidiary GB Pharma, GBC has transformed P113 technology into the oh care® consumer healthcare line, featuring:
• Gentle antimicrobial mouthwash
• On-the-go oral spray
• P113-powered toothpaste
The oh care® series embodies “Science × Safety × Daily Wellness”:
• Alcohol-free, fluoride-free formulations
• Free from preservatives, colorants, and artificial sweeteners
• Designed for all ages, including infants, pregnant women, and seniors
Beyond Oral Care: Expanding the Vision
The potential of P113 goes beyond oral health.
GBC is collaborating with research partners to explore applications in skin protection, mucosal care, and immune modulation, paving the way for next-generation consumer healthcare solutions.
Conclusion
P113 is more than an innovation — it’s a bridge between science and daily life.
By integrating P113 into the oh care® series, GBC sets a new benchmark for safe, effective, and science-driven oral care, embodying our vision:
Cervical cancer remains one of the most preventable cancers when detected early, yet traditional cytology workflows are labor-intensive and time-consuming. GBC, in partnership with Danner Lab, has introduced an AI-powered digital pathology platform that automates the entire screening process, improving accuracy and efficiency.
How It Works: Thin-Layer Smears + AI Deep Learning
Using thin-layer smear preparation, cellular debris and background noise are removed, producing a clear, single-cell layer. Each specimen generates 2,300+ high-resolution images, which are analyzed by a deep learning model trained on the Bethesda classification system—the global standard for cervical cytology.
This AI-driven process can automatically classify cells, flagging potential abnormalities for review, and significantly reducing manual workload.
Key Advantages
• Higher Accuracy: AI improves consistency and reduces human error.
• Regulatory Compliance: Overcomes limitations such as Taiwan and U.S. regulatory caps of ≤80 slides/day per cytologist.
• Scalable Applications: Supports not only cervical cancer screening but broader digital pathology and drug discovery workflows.
Why It Matters
By combining AI with optimized smear preparation, GBC is reshaping traditional cytology into a high-throughput, precision-driven, and scalable process. This represents a breakthrough for both population-based screening programs and personalized medicine, ensuring patients receive earlier, more accurate results.
Real-Time PCR (qRT-PCR), also known as quantitative PCR, leverages primers and probes (commonly TaqMan chemistry) to produce fluorescence as target DNA is amplified—enabling instant quantitative detection. The Ct value, or cycle threshold, is the number of cycles required for fluorescence to exceed a predefined threshold.
A low Ct value indicates high initial viral load, while a high Ct value suggests lower viral presence. For example, a Ct of 25 implies detection occurred after approximately 2²⁵ amplification cycles.
2. GBC’s Ct Threshold and Sensitivity
GBC’s GB SARS-CoV-2 Real-Time RT-PCR kit (4PCO052E) has a Ct cutoff of 37 cycles and a limit of detection (LoD) of 1,000 copies/mL—demonstrating high analytical sensitivity.
3. Why Ct Values Aren’t Absolute Indicators
Though Ct values are useful, they aren’t definitive. Ct can vary due to:
• Sample collection method, specimen type, and quality
• Reagent design, brand, and lot variability
• Timing of sample collection relative to disease progression
Thus, clinical context and patient symptoms remain primary for decision-making.
4. Interpreting Ct in High-Volume Settings
During surges, some regions may adjust Ct thresholds for ending isolation to balance diagnostic rigor with healthcare capacity. In these contexts, Ct should be interpreted cautiously to avoid premature release from isolation and ensure patient and public safety.
5. Clinical Takeaways
• Low Ct values usually correlate with high infectivity or early disease onset.
• High Ct values may reflect late-stage infection, testing delays, or reduced risk of transmission.
• Ct is a useful reference point but should never replace assessment based on symptoms and clinical judgment.
With recurring COVID-19 case surges, many regions—including Taiwan since April 2022—struggled to maintain PCR testing capacity. Rapid antigen tests gained traction because they are easy, fast, and suitable for mass screening.
2. How Rapid Antigen Tests Work (Lateral Flow Assay)
Rapid tests use lateral flow immunochromatography, composed of four key components:
• Sample pad → receives nasal or saliva sample
• Conjugate pad → carries monoclonal antibodies bound to colloidal gold
• Nitrocellulose membrane → displays results
• Wicking pad → ensures liquid flow via capillary action
If viral antigen (typically nucleocapsid protein) is present, you’ll see both T (test) and C (control) lines—indicating a positive result. Without antigen, only the C line appears, indicating a negative result.
3. RT-PCR: The Gold Standard
PCR amplifies viral RNA (converted to cDNA) using a specific primer-probe design, increasing target DNA exponentially—thus offering much higher sensitivity and specificity than antigen tests. GBC’s GB SARS-CoV-2 RT-PCR kit (4PCO052E) features:
• Ct threshold of 37 cycles
• Detection limit: 1,000 copies/mL
• Capable of detecting low viral loads through 2³⁷-fold amplification
4. Rapid antigen tests and RT-PCR serve different purposes in COVID-19 diagnostics, each with distinct strengths:
Speed — Rapid tests deliver results in about 15 minutes, while RT-PCR usually takes several hours.
Ease of Use — Rapid tests can be performed by anyone, even at home. RT-PCR requires trained personnel and specialized equipment.
Sensitivity — RT-PCR is far more sensitive, capable of detecting very low viral loads. Rapid tests are better at identifying cases with high viral loads.
Use Cases — Rapid tests are ideal for mass screening and self-checks, while RT-PCR remains the gold standard for clinical confirmation and early detection.
In short, rapid tests are designed for convenience and speed, whereas RT-PCR ensures maximum accuracy and plays a critical role in healthcare decision-making.
5. Interpreting Discordant Results
Occasionally, a rapid test may show positive, and PCR negative, or vice versa. This can be due to:
